Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 14Gastro-enteropancreatic neuroendocrine tumor 4Carcinoid Tumor 3Serotonin Syndrome 1Neuroendocrine Tumors in Lung 1Neoplastic Cells, Circulating 1Gastrointestinal Neoplasms 1Flushing 1Diarrhea 1Carcinoma, Hepatocellular 1Adenoma, Islet Cell 1Acromegaly 1

Interventions

repotrectinib 1pralsetinib 1lutetium Lu 177 dotatate 1lanreotide 1copper dotatate CU-64 1alectinib 1Surveys and Questionnaires 1Referral and Consultation 1Quality of Life 1Poly(ADP-ribose) Polymerase Inhibitors 1Nivolumab 1Lutetium-177 1Lutetium 1Ipilimumab 1Cryotherapy 1Acupuncture Therapy 1Acupressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × lanreotide × NET × Clear all
NCT02859064 2023-12-05

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

SCRI Development Innovations, LLC

Phase 2 Terminated
6 enrolled 12 charts
EndocrineGastrointestinalNET

Carcinoid Tumor, Gastrointestinal Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡